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Resistance in Neisseria gonorrhoeae to all available therapeutic antimicrobials has
emerged and new efficacious drugs for treatment of gonorrhea are essential.
The topoisomerase II inhibitor ETX0914 (also known as AZD0914) is a new
spiropyrimidinetrione antimicrobial that has different mechanisms of action from all
previous and current gonorrhea treatment options. In this study, the N. gonorrhoeae
resistance determinants for ETX0914 were further described and the effects of
ETX0914 on the growth of N. gonorrhoeae (ETX0914 wild type, single step selected
resistant mutants, and efflux pump mutants) were examined in a novel in vitro time-
kill curve analysis to estimate pharmacodynamic parameters of the new antimicrobial.
For comparison, ciprofloxacin, azithromycin, ceftriaxone, and tetracycline were also
examined (separately and in combination with ETX0914). ETX0914 was rapidly
bactericidal for all wild type strains and had similar pharmacodynamic properties
to ciprofloxacin. All selected resistant mutants contained mutations in amino acid
codons D429 or K450 of GyrB and inactivation of the MtrCDE efflux pump fully
restored the susceptibility to ETX0914. ETX0914 alone and in combination with
azithromycin and ceftriaxone was highly effective against N. gonorrhoeae and synergistic
interaction with ciprofloxacin, particularly for ETX0914-resistant mutants, was found.
ETX0914, monotherapy or in combination with azithromycin (to cover additional sexually
transmitted infections), should be considered for phase III clinical trials and future
gonorrhea treatment.
Keywords: gonorrhea, treatment, antimicrobial resistance, time-kill curve analysis, pharmacodynamics, DNA
topoisomerase II inhibitor, ETX0914
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INTRODUCTION
The sexually transmitted infection gonorrhea, caused by
Neisseria gonorrhoeae, is a signiﬁcant global public health
concern (World Health Organization [WHO], 2008; Centers for
Disease Control and Prevention [CDC], 2012; World Health
Organization and Department of Reproductive Health and
Research, 2012a,b). In vitro resistance, including high-level
resistance, to the last available option for ﬁrst-line empirical
antimicrobial monotherapy, the third-generation extended-
spectrum cephalosporin ceftriaxone, has emerged (Ohnishi
et al., 2011; Cámara et al., 2012; Ison, 2012; Unemo and
Nicholas, 2012; Unemo et al., 2012a; Unemo and Shafer,
2014). Sporadic failures to treat pharyngeal gonorrhea with
ceftriaxone have also been veriﬁed in several countries (Ohnishi
et al., 2011; Unemo and Nicholas, 2012; Unemo et al., 2011,
2012b; Chen et al., 2013; Read et al., 2013; Golparian et al.,
2014a).
New drugs with mechanisms of action that are distinct from
previously used antimicrobials are urgently needed to forestall
scenarios in which gonorrhea becomes very diﬃcult to treat or
even untreatable. Spiropyrimidinetriones represent a recently
developed class of antimicrobials that inhibit bacterial DNA
type II topoisomerases, i.e., DNA gyrase and topoisomerase
IV (Basarab et al., 2015). Their mechanisms of action diﬀers
from that of all other available antimicrobials, including DNA
topoisomerase inhibitors such as the ﬂuoroquinolones (Mayer
and Janin, 2014; Huband et al., 2015; Kern et al., 2015).
ETX0914 (also known as AZD0914; Entasis Therapeutics,
Waltham, MA, USA) is a novel, not yet clinically used or
commercially available, spiropyrimidinetrione, aimed for oral
administration, with potent in vitro activity against key Gram-
positive, fastidious Gram-negative, atypical and anaerobic
bacterial species, including isolates with high-level resistance
to ﬂuoroquinolones (Huband et al., 2015). ETX0914 was
recently shown to have an excellent in vitro activity against
a wide variety of clinical N. gonorrhoeae strains, including
many multidrug-resistant (MDR) and extensively drug-resistant
(XDR) strains. The minimum inhibitory concentration (MIC)
values for ETX0914 ranged between ≤0.004 and 0.25 mg/L and
no cross-resistance to the ﬂuoroquinolone ciproﬂoxacin
or other antimicrobials previously or currently used in
the treatment of gonorrhea was observed (Jacobsson et al.,
2014).
ETX0914 stabilizes and arrests the cleaved covalent complex
of DNA gyrase with double-strand broken DNA and thus
blocks religation of the double-strand cleaved DNA to form
fused circular DNA (Mayer and Janin, 2014; Huband et al.,
2015; Kern et al., 2015). Accordingly, ETX0914 inhibits
DNA biosynthesis and replication by an accumulation of
DNA double strand cleavages and prevention of religation,
in contrast to the ﬂuoroquinolones (Mayer and Janin, 2014;
Palmer et al., 2014; Huband et al., 2015; Kern et al., 2015).
In N. gonorrhoeae, resistance to ETX0914 has been selected
in vitro in a few gonococcal strains and the resistance mutations
D429N and/or K450T, occurring at low frequencies, were
mapped to gyrB (Alm et al., 2015). The eﬀects on the MIC
of ETX0914 by other gyrB mutations and possible mutations
in gyrA, parC, parE, or porB, encoding the PorB porin,
genes as well as over-expression of eﬄux pumps remain
unknown.
The evaluation of a new antimicrobial includes an
assessment of the relationship between exposure to the
drug and bacterial growth (Drusano, 2004). The MIC gives
a biological measure of the susceptibility of a pathogen to
an antimicrobial, but does not give any information about
how diﬀerent antimicrobial concentrations aﬀect bacterial
growth over time (Li et al., 1999). Regoes et al. (2004)
introduced the concept of pharmacodynamic functions,
which are related to maximum eﬀect (Emax) models, to examine
the relationship between antimicrobial concentration and
bacterial growth and death rates, estimated from in vitro
time-kill curves. Antimicrobials with identical MICs but a
diﬀerent pharmacodynamic function can have diﬀerences
in antimicrobial eﬃcacy. Appropriate in vitro growth and
pharmacodynamic assays for the obligate human pathogen
N. gonorrhoeae have been lacking and would be exceedingly
valuable.
The aims of the present study were to extend the
characterization of the resistance determinants for ETX0914
and to investigate how ETX0914 aﬀects the growth of
N. gonorrhoeae (ETX0914 wild type, single step resistant
mutants and eﬄux pump mutants) using a novel in vitro time-
kill curve analysis to estimate pharmacodynamic parameters
of the new antimicrobial (Foerster et al., 2015). The results
for ETX0194 were compared to those of ciproﬂoxacin,
azithromycin, ceftriaxone, and tetracycline. Combinations
of these antimicrobials with ETX0194 were also further
investigated using checkerboard analysis and time-kill curve
analysis.
MATERIAL AND METHODS
Bacterial Strains
The international N. gonorrhoeae reference strains WHO F,
WHOO,WHOP (Unemo et al., 2009), the ceftriaxone high-level
resistant XDR strain H041 (Ohnishi et al., 2011), and single step
selected resistant mutants of WHO O and P were included in
this study. The relevant phenotypic and genetic characteristics of
these parental strains are summarized in Table 1. All strains were
cultured on GCAGP agar plates (3.6% Difco GC Medium Base
agar [BD, Diagnostics, Sparks, MD, USA] supplemented with 1%
hemoglobin [BD, Diagnostics], 1% IsoVitalex [BD, Diagnostics]
and 10% horse serum) for 18–20 h at 37◦C in a humid 5%
CO2-enriched atmosphere.
Antimicrobial Susceptibility Testing
The MICs (mg/L) of ETX0914 (Entasis Therapeutics, Waltham,
MA, USA) were determined by agar dilution technique, in
accordance with the Clinical and Laboratory Standards Institute
(CLSI) guidelines (Clinical and Laboratory Standards Institute,
2014) and as previously described (Jacobsson et al., 2014).
Susceptibility to ciproﬂoxacin, azithromycin, ceftriaxone, and
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TABLE 1 | Relevant phenotypic and genetic characteristics of Neisseria gonorrhoeae strains examined.
Strain characteristics WHO F WHO O WHO P H041
ETX0914 (MIC, mg/L) 0.064 0.125 0.25 0.125
Ciprofloxacin (MIC, mg/L) 0.004 0.008 0.004 >32
Azithromycin (MIC, mg/L) 0.125 0.25 2 1
Ceftriaxone (MIC, mg/L) <0.002 0.032 0.032 4
Tetracycline (MIC, mg/L) 0.25 1 0.5 4
gyrA codon 91, 95 WT WT WT S91F, D95N
gyrB codon 429 WT WT WT WT
mtrR promoter region 13 bp inverted repeat WT Deletion of A A→C substitution deletion of A
mtrR coding region frame-shift mutation — — T insert at bp 60 –
porB1b codon 120 NA G120K WT G120K
porB1b codon 121 NA A121D A121D A121D
NG-MAST ST ST3303 ST495 ST3305 ST4220
MLST ST10934 ST1902 ST8127 ST7363
MIC, minimum inhibitory concentration; WT, wild type; NA, not applicable; NG-MAST, N. gonorrhoeae multiantigen sequence typing; ST, sequence type; MLST, multi-locus
sequence typing. Data from previous publications (Unemo et al., 2009; Ohnishi et al., 2011) also included.
tetracycline was determined using the Etest method (bioMérieux,
Marcy l’Etoile, France) in accordance with the manufacturer’s
instructions, on GCRAP agar plates (3.6% Difco GC Medium
Base agar [BD, Diagnostics] supplemented with 1% hemoglobin
[BD, Diagnostics] and 1% IsoVitalex [BD, Diagnostics]).
Selection of Single Step
ETX0914-Resistant Mutants
Resistant mutants were selected on GC agar plates (3.6% Difco
GC Medium Base agar [BD, Diagnostics] supplemented with
1% IsoVitalex [BD, Diagnostics]) containing 2-fold increasing
concentrations of ETX0914 (0.032-8 mg/L). Brieﬂy, WHO F,
WHO P, WHO O, and H041 (Table 1) were cultured on GCAGP
agar plates for 18–20 h at 37◦C in a humid 5% CO2-enriched
atmosphere. Fresh cultures (18 h) from 10 agar plates were pooled
and suspended in 2 mL of sterile PBS. A dilution series (ranging
from 1:100 to 1:1014) of the bacterial suspension in PBS was
plated on compound free GC agar plates. Undiluted 100 μL
aliquots were plated on ETX0914-containing GC agar plates and
grown for 48 h at 37◦C in a humid 5% CO2-enriched atmosphere.
Selected resistant mutants that grew at the highest ETX0914
concentration were sub-cultured for 24 h on GCAGP agar plates
and frozen at −70◦C.
gyrB Sequencing
To identify the ETX0914 resistance mutations in the selected
mutants, gyrB was ampliﬁed by PCR and sequenced as described
(Jacobsson et al., 2014).
Generation of Efflux Pump Mutants
The mtrD, macA, and norM genes, coding for components of
the MtrCDE, MacAB and NorM eﬄux pumps, were inactivated
in strains by spot transformation (Gunn and Stein, 1996) using
0.1 μg of chromosomal DNA from genetic derivatives of strain
FA19 or wild type strain FA19 bearing insertions in mtrD
(strain KH14;mtrD::kan),macA (strain BR54macA::spc) or norM
(strain FA19 norM::kan), as previously described (Golparian
et al., 2014b).
Time-kill Experiments
Time-kill curve analyses were performed by culturing the
N. gonorrhoeae strains in liquid Graver–Wade (GW) medium
(Wade and Graver, 2007). Eleven antimicrobial-concentrations
in doubling dilutions ranging from 0.016 × MIC to 16 × MIC,
in Sarstedt 96-well round bottom microtiter plates (360 μL
wells) were examined for the following antimicrobials: ETX0914
(Entasis Therapeutics), ciproﬂoxacin (Sigma Aldrich, USA),
azithromycin (Sigma Aldrich), ceftriaxone (Sigma Aldrich),
and tetracycline (Sigma Aldrich). Growth curves were initially
performed to conﬁrm that all strains would reach a stable early-
to mid-log phase after 4 h of pre-incubation in antimicrobial-
free GW medium. Subsequently, a 0.5 McFarland inoculum of
N. gonorrhoeae was prepared in sterile PBS from cultures grown
on GCAGP agar plates for 18–20 h at 37◦C in a humid 5% CO2-
enriched atmosphere. For each strain, 30 μL of the inoculum was
diluted in 15 mL pre-warmed antimicrobial-free GW medium
(37◦C) and 90 μL per well was dispersed in Sarstedt 96-well
round bottom microtiter plates (360 μL wells). The plates were
pre-incubated for 4 h shaking at 150 rpm, 35◦C in a humid
5% CO2-enriched atmosphere. To each well containing 90 μL
of pre-incubated bacteria, 10 μL of one of the antimicrobial
concentrations (or PBS) was added, resulting in eight identical
rows containing bacteria exposed to 11 diﬀerent antimicrobial
concentrations and one untreated control. Colony forming units
(CFUs) were measured using a modiﬁedMiles andMisra method
as previously described (Chen et al., 2003). At 0, 1, 2, 3, 4,
5, and 6 h after exposure, the total volume of one row was
removed using a multichannel pipette and diluted in PBS in
six subsequent 1:10 dilutions. Ten μL droplets of each dilution
were spotted on GCRAP agar plates (diameter 14 cm; pre-dried
with open lid in a sterile environment for 30–60 min). After
drying the plates (∼5–10 min), they were incubated for 24 h
at 37◦C in a humid 5% CO2–enriched atmosphere. Colonies
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were then counted and numbers extrapolated to CFUs/mL by
multiplying the initial volume of 10 μL with 100 and the dilution
factor.
Pharmacodynamic Function and
Hierarchical Clustering
The results of the novel in vitro time-kill curve analysis were
used to estimate pharmacodynamic parameters of antimicrobials.
In brief, the bacterial net growth rates were estimated from
changes in the density of viable bacteria (CFU/mL) between 0
and 6 h of the time-kill experiments, as previously described
(Foerster et al., 2015). A pharmacodynamic function was then
ﬁtted to the bacterial net growth rates in response to diﬀerent
concentrations of antimicrobials as earlier detailed (Regoes
et al., 2004). In this pharmacodynamic function, the bottom
asymptote (parameter ψmin) and top asymptote (parameter
ψmax) represent the minimal and maximal bacterial net growth
rate at high concentrations and in absence of antimicrobial,
respectively. The slope of the sigmoidal curve at the inﬂection
point (Hill coeﬃcient or parameter κ) describes the steepness
of the relationship between bacterial growth and antimicrobial
concentration. The pharmacodynamic MIC (parameter zMIC)
is the antimicrobial concentration that results in a net growth
rate of zero. The heatmap was produced by plotting the
numeric values of the minimal bacterial net growth rate
at high concentrations of antimicrobial (ψmin) and the Hill
coeﬃcient (κ; steepness of the relationship between bacterial
growth and antimicrobial concentration) in a color gradient
from red (high values) to blue (low values). The ﬁtting
routine was based on self-starter models as implemented in
the R package drc (Ritz and Streibig, 2005). The hierarchical
clustering was performed using the complete linkage algorithm
as implemented in the package heatmap3 (Zhao et al.,
2014). The distances in the resulting dendrogram represented
similarities between strains and antimicrobials. Further details
regarding ﬁtting the pharmacodynamic function to the bacterial
net growth rates in response to diﬀerent concentrations of
antimicrobials and all estimated parameters using the function
in the present study have been summarized in Supplementary
Table S1.
Checkerboard Assay
Checkerboard assays for examination of antimicrobial
combinations were performed as previously described
(Meletiadis et al., 2010), with minor modiﬁcations. Doubling
dilution series for both antimicrobials starting at 16 × MIC
of each antimicrobial (combined in 1:1 ratios) were prepared
in PBS. Five micro liter of each of the dilution series were
combined in a Sarstedt 96 well round bottom microtiter
plate (360 μL wells), resulting in a gradient that contained
the highest concentration of drugs in well A1. A bacterial
suspension in GW medium (Wade and Graver, 2007),
containing approximately 105 CFU/mL from 18–20 h old
culture on GCAGP agar plates was prepared and incubated for
4 h at 150 rpm, 37◦C, humid 5% CO2-enriched atmosphere
in a 50 mL Erlenmeyer ﬂask. These cultures were added
to the checkerboard plates containing the antimicrobial
combinations (90 μL culture + 10 μL antimicrobial dilution per
well). Bacterial growth in each well was assessed visually
after 24 h of incubation with a magnifying glass. The
isoeﬀective combinations were determined as the lowest
drug concentrations showing no visual growth (optically clear
well).
Fractional Inhibitory Concentration Index
(FICI) Analysis
The fractional inhibitory concentration index (FICI) was
calculated as follows (White et al., 1996):
FICI= FICA + FICB =MICcombA /MICaloneA + MICcombB /MICaloneB
Among all the FICIs calculated for all isoeﬀective combinations,
the minimum FIC (FICImin) and the maximum FIC (FICImax)
were reported in order to identify synergistic and antagonistic
interactions. Cut-oﬀ criteria of ≤0.5 for synergy and >4 for
antagonism were applied (Odds, 2003). The FICI was also
calculated for the zMIC values of the time-kill experiments,
applying the same criteria. To calculate the concentrations
of both antimicrobials in the combination, the ratio was
calculated dividing zMIC/(maximal concentration A + maximal
concentration of B). The antimicrobial interaction was only
considered to be veriﬁed if checkerboard and time-kill assay
results agreed.
RESULTS
Selection of Single Step
ETX0914-Resistant Mutants
Single step mutants were selected at very low frequencies on GC
agar plates (<1.9 × 10−14) from the reference strains WHO
F, O, and P, but not for H041. All selected resistant mutants
contained a single amino acid alteration (D429N, D429A, or
K450T) in GyrB, which resulted in ETX0914 MICs of 0.5–
4 mg/L. However, these gyrB mutations did not signiﬁcantly
aﬀect the MICs of ciproﬂoxacin, azithromycin, ceftriaxone, and
tetracycline (Table 2). The selected resistant mutants OM-5 and
PM-4 were selected for further analysis.
Effect on ETX0914 Susceptibility by
Inactivation of Efflux Pumps
By inactivation of the MtrCDE eﬄux pump, susceptibility to
ETX0914 was fully restored (MIC= 0.125mg/L) in both resistant
mutants and the ETX0914 MIC values in the ETX0914 wild
type WHO F, O, P and H041 strains decreased signiﬁcantly
(3- to 5-fold). Additional inactivation of the MacAB or NorM
eﬄux pumps decreased the MIC of ETX0914 in the H041 strain
(from 0.125 mg/L to 0.008 mg/L), but these inactivations had no
signiﬁcant eﬀect on the MICs of ETX0914 in the other strains.
As previously shown (Golparian et al., 2014b), the inactivation of
theMtrCDE eﬄux pump signiﬁcantly increased the susceptibility
also to azithromycin in all strains and to ceftriaxone in most
strains (Table 3).
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TABLE 2 | Single step selected resistant mutants, gyrB mutations, frequency of selected mutations, and effects on MIC of examined antimicrobials.
Isolate Description gyrB mutation Frequency of
mutation (CFU/mL)a
MIC (mg/L)b
AZM ETX0914 CIP CRO TET
WHO F WT WT 0.125 0.064 0.004 0.004 0.25
FM-1 First step mutant D429N <3 × 10−14c 0.125 0.5 0.008 <0.002 0.5
FM-3 First step mutant D429N <3 × 10−14c 0.125 0.5 0.008 <0.002 0.25
FM-5 First step mutant D429N <3 × 10−14c 0.125 0.5 0.008 <0.002 0.25
FM-6 First step mutant D429N <3 × 10−14c 0.125 0.5 0.008 <0.002 0.25
FM-7 First step mutant D429N <3 × 10−14c 0.125 0.5 0.016 <0.002 0.5
FM-8 First step mutant D429N <3 × 10−14c 0.125 0.5 0.008 <0.002 0.5
WHO O WT WT 0.25 0.125 0.008 0.032 1
OM-1 First step mutant D429N <3 × 10−14c 0.5 1 0.032 0.016 2
OM-2 First step mutant D429N <3 × 10−14c 0.5 1 0.032 0.016 2
OM-3 First step mutant D429N <3 × 10−14c 0.5 1 0.032 0.016 2
OM-4 First step mutant D429N <3 × 10−14c 0.5 1 0.032 0.016 2
OM-5 First step mutant D429N <3 × 10−14c 0.5 1 0.032 0.032 2
OM-6 First step mutant D429N <3 × 10−14c 0.5 0.5 0.032 0.016 2
WHO P WT WT 2 0.25 0.004 0.004 0.5
PM-1 First step mutant D429N 2 × 10−14 4 2 0.008 0.004 1
PM-2 First step mutant D429N 2 × 10−14 4 4 0.032 0.008 1
PM-3 First step mutant D429N 2 × 10−14 4 2 0.008 0.004 1
PM-4 First step mutant D429N 2 × 10−14 4 4 0.032 0.004 1
PM-5 First step mutant D429A 2 × 10−14 4 1 0.008 0.004 2
PM-6 First step mutant D429N 2 × 10−14 4 2 0.008 0.008 2
PM-7 First step mutant D429N 2 × 10−14 4 2 0.008 0.008 2
PM-8 First step mutant D429N 2 × 10−14 2 2 0.004 0.004 1
PM-9 First step mutant K450T 2 × 10−14 4 2 0.008 0.008 1
PM-10 First step mutant D429N 2 × 10−14 8 2 0.008 0.008 1
H041 Parent WT 1 0.125 >32 8 4
H041-1 No mutanta – – – – – – -
H041-2 No mutanta – – – – – – –
H041-3 No mutanta – – – – – – –
H041-4 No mutanta – – – – – – –
H041-5 No mutanta – – – – – – –
H041-6 No mutanta – – – – – – –
aUsing a more nutritious agar medium (GCAGP agar plates, including also 1% hemoglobin and 10% horse serum) and 72 h culture selected resistant mutants in all four
strains, that is, with a frequency of 8 × 10−9 for H041, 5 × 10−9 for WHO F, and 1 × 10−8 for WHO P and WHO O. bOnly whole MIC doubling dilutions from the Etest
reported. cFrequency below limit of detection, i.e., numbers of CFUs that could be counted. AZM, azithromycin; CIP, ciprofloxacin; CRO, ceftriaxone; TET, tetracycline;
WT, wild type.
Time-kill Curve Analysis
The phenotypic eﬀects of ETX0914 on the ETX0914 wild type
WHO F, O, P and H041 strains, as well as the resistant OM-
5 and PM-4 mutants were assessed in time-kill curve analysis.
Similar time-kill curve proﬁles were obtained for all the wild
type strains (Figures 1A–C,E). The CFUs of all wild type strains
were reduced to below the limit of detection (100 CFU/mL)
at 8 × MIC and 16 × MIC, and killed, albeit more slowly
at 2 × MIC and 4 × MIC, within 4 h of exposure. The
net growth rates decreased quickly in the ﬁrst hour and
then leveled oﬀ. ETX0914 also killed the resistant mutants
OM-5 and PM-4 at concentrations above the MIC but the
mutants were above the limit of detection (100 CFU/mL) even
at the highest ETX0914 concentration (16 × MIC) for the
exposure time of 6 h. The decrease in net growth rates in
response to increased ETX0914 concentrations was smaller and
more gradual compared to their respective wild type strains
(Figures 1D,F).
Pharmacodynamic Functions
The net growth rates for each ETX0914 concentration examined
were calculated and a pharmacodynamic function ﬁtted to the
data (Figure 2). The minimal bacterial net growth rate at
high concentrations of antimicrobial (parameter ψmin) was not
identiﬁable (below ∼10 h−1) for all the wild type strains and
was substantially higher for both the resistant mutants (−1.2
for OM-5 and −1.4 for PM-4). The steepness of the slope of
the pharmacodynamic relationship (Hill coeﬃcient; parameter
κ) did not diﬀer for the wild type strains compared to the
resistant mutants. The pharmacodynamic zMIC (concentration
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TABLE 3 | Minimum inhibitory concentration (MICs)a,b in Neisseria gonorrhoeae wild type strains and selected ETX0914-resistant mutants after
inactivation of the MtrCDE, MacAB, and NorM efflux pumps.
Bacterial strain ETX0914 CIP AZM CRO TET
WHO O WT 0.125 0.008 0.25 0.032 1
MtrCDE IA 0.008 0.004 0.064 0.004 0.5
MacAB IA 0.125 0.008 0.5 0.032 2
NorM IA 0.125 0.008 0.5 0.032 2
OM-5 1 0.032 0.5 0.064 2
MtrCDE IA 0.125 0.008 0.064 0.008 1
MacAB IA 1 0.032 0.5 0.064 2
NorM IA 1 0.032 0.5 0.032 2
WHO P WT 0.25 0.004 2 0.004 0.5
MtrCDE IA 0.008 0.004 0.064 0.004 0.25
MacAB IA 0.25 0.008 4 0.008 1
NorM IA 0.25 0.008 4 0.008 2
PM-4 4 0.016 4 0.008 1
MtrCDE IA 0.125 0.008 0.064 0.004 1
MacAB IA 4 0.016 2 0.008 1
NorM IA 4 0.016 2 0.008 2
WHO F WT 0.064 0.004 0.125 <0.002 0.25
MtrCDE IA 0.008 0.004 0.064 <0.002 0.25
MacAB IA 0.064 0.004 0.125 <0.002 0.25
NorM IA 0.064 0.004 0.25 <0.002 1
H041 WT 0.125 >32 1 4 2
MtrCDE IA 0.004 16 0.064 1 1
MacAB IA 0.008 >32 0.25 2 0.5
NorM IA 0.008 >32 0.5 2 4
AZM, azithromycin; CIP, ciprofloxacin; CRO, ceftriaxone; TET, tetracycline; WT, wild type; IA, Inactivation. aOnly whole MIC doubling dilutions in mg/L from the Etest
reported. bData from previous publication (Golparian et al., 2014b) also included.
that results in net growth rate of zero) of ETX0914 was
within one MIC doubling dilution of those obtained with
agar dilution technique. The pharmacodynamic parameter
estimates for ETX0941 were compared to those of ciproﬂoxacin,
azithromycin, ceftriaxone, and tetracycline (Figure 3). In general,
each antimicrobial resulted in a unique pharmacodynamic
proﬁle. For ciproﬂoxacin, the “minimal growth rate” (parameter
ψmin) was low for all four wild type strains (Figure 3B). For
the highly ciproﬂoxacin-resistant strain H041, the “minimal
growth rate” (ψmin) was below detection limit (100 CFU/mL)
and did not level oﬀ in the range of examined concentrations
(<−15). However, the “minimal growth rate” (ψmin) was
signiﬁcantly increased in both the resistant mutants, i.e.,
similar as was observed for ETX0914. The high zMIC of
ciproﬂoxacin in H041 shifted its curve away from the curves
of the susceptible strains (Figure 3B). Ciproﬂoxacin and
ETX0914 had the lowest “minimal growth rates” (ψmin), followed
by azithromycin, ceftriaxone, and tetracycline. Tetracycline
exposure resulted in “minimal growth rate” (ψmin) values
relatively close to zero in all strains with exception of WHO F
(Figure 3E).
In the hierarchical clustering of the “minimal growth rate”
(ψmin) (Figure 4A), ETX0914 and ciproﬂoxacin clustered
together. Azithromycin showed relatively close similarity to
this cluster, followed by ceftriaxone and tetracycline. The
two resistant mutants OM-5 and PM-4 clustered together
and could be clearly distinguished from the wild type
strains. Hierarchical clustering did not reveal any clearly
distinguishable pattern between the steepness of the slope of
the pharmacodynamic relationship (Hill coeﬃcient; parameter
κ) for resistant mutants and the wild type strains. Only
the XDR strain H041 appeared distinctly separated from
the other strains in this clustering. The highest value of
the Hill coeﬃcient (steepest slope of the pharmacodynamic
relationship) were obtained for ciproﬂoxacin (Figure 4B).
The maximal growth rate in the absence of antimicrobial
(ψmax parameter) ranged between 0.3 and 1.4 h−1 for the
susceptible strains, corresponding to a bacterial doubling time
of 30–139 min. This parameter was substantially lower in
the resistant mutants compared to their respective wild type
strains (Figure 4C). Overall, the pharmacodynamic zMIC values
were very similar to the MICs determined using agar dilution
technique and/or Etest (Spearman rank correlation coeﬃcient
0.95). The 95% conﬁdence interval for the regression line was
substantially wider for the very low and high MIC values
(Figure 4D).
Checkerboard Assay and Time-kill Curve
Analysis for Antimicrobial Combinations
The checkerboard assay identiﬁed an indiﬀerent eﬀect
(FICI = 0.5–3) for most antimicrobial combinations and
strains (Table 4). However, the combination of ETX0914 and
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FIGURE 1 | Time-kill curves of six different Neisseria gonorrhoeae strains with ETX0914: H041 (A), WHO F (B), WHO O (C), OM-5 (D; in vitro selected
resistant mutant from WHO O), WHO P (E), and PM-4 (F; in vitro selected resistant mutant from WHO P). Untreated controls are shown in red, each line
corresponds to a doubling concentration of the antimicrobial, and circles indicate each measured time point. The limit of detection in the assay was 100 colony
forming units (CFUs)/mL.
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FIGURE 2 | Pharmacodynamic functions based on the time-kill curve data for ETX0914 and six different Neisseria gonorrhoeae strains: H041 (A),
WHO F (B), WHO O (C), OM-5 (D; in vitro selected resistant mutant from WHO O), WHO P (E), and PM-4 (F; in vitro selected resistant mutant from
WHO P). The bacterial growth rates per hour derived from linear regression on time-kill curves for each ETX0914 concentration are plotted. Growth in absence of
ETX0914 was plotted as a red circle, at a tenth of the lowest concentration to allow plotting on a log scale, and decreasing ETX0914 concentrations are shown from
dark to light blue color.
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FIGURE 3 | Comparisons of pharmacodynamic functions based on the time-kill curve data for ETX0914 (A), ciprofloxacin (B), azithromycin (C),
ceftriaxone (D), and tetracycline (E) and six different Neisseria gonorrhoeae strains: H041, WHO F, WHO O, OM-5 (in vitro selected resistant mutant
from WHO O), WHO P, and PM-4 (in vitro selected resistant mutant from WHO P). The bacterial growth rates per hour derived from linear regression on
time-kill curves for each antimicrobial concentration are plotted.
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FIGURE 4 | Pharmacodynamic properties of ETX0914 in direct comparison to ciprofloxacin, azithromycin, ceftriaxone and tetracycline. (A) Shows a
hierarchical clustering for the minimal bacterial net growth rate at high concentrations of antimicrobial (parameter ψmin), (B) for the steepness of the slope of the
pharmacodynamic function (Hill coefficient, κ), (C) shows the maximal growth rate in the absence of antimicrobial (parameter ψmax) for each strain calculated as
mean and standard error from all independent experiments (Supplementary Table S1) and (D) the correlation between MICs measured with conventional methods
(Etest or agar dilution technique; values below <0.002 mg/L and >32 mg/L (Etest detection limit) were excluded from the analysis) and pharmacodynamic MIC
(zMIC). The linear regression line is drawn in black and the confidence interval shaded in gray. The heatmap was produced by plotting the numeric values of ψmin and
the Hill coefficient (κ) in a color gradient from red (high values) to blue (low values). The hierarchical clustering was performed using the complete linkage algorithm as
implemented in the package heatmap3 (Zhao et al., 2014). The distances in the resulting dendrogram represented similarities between strains and antimicrobials.
ciproﬂoxacin indicated synergism for the resistant mutants
OM-5 and PM-4 in both the checkerboard assay (FICI range:
0.4–1 for both mutants) and time-kill curve analysis (FICI:
0.1 and 0.10, respectively). The combination of ETX0914
and ciproﬂoxacin also indicated synergism for the wild type
strain WHO F in the time-kill curve analysis (FICI: 0.4),
and in the checkerboard assays the corresponding FICI was
at the breakpoint for synergy, that is, 0.5. Furthermore, the
combination of ETX0914 and ceftriaxone indicated synergism
for the wild type WHO P strain and its isogenic selected
resistant mutant (PM-4) in the time-kill curve analysis (FICI:
0.3 and 0.02, respectively), and in the checkerboard assays the
corresponding FICIs were at the breakpoint for synergy, that
is, 0.5–0.6. The only antagonism indicated in the checkerboard
assays was for the combination of ETX0914 and tetracycline
and the XDR strain H041 (FICI range: 2–8), but no antagonism
was detected in the time-kill curve analysis (FICI = 1.9).
A qualitative comparison of the time-kill curves revealed
that ETX0914 combined with ciproﬂoxacin or azithromycin
resulted in a more rapid bactericidal eﬀect compared to
ETX0914 alone (Supplementary Figure S1). For the resistant
mutants, the “minimal growth rate” (ψmin) was signiﬁcantly
lower with both these combinations compared to ETX0914
alone.
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TABLE 4 | Fractional inhibitory concentration index (FICI) from the
checkerboard assay and time-kill curve analysis.
Strain Antimicrobial
combination
Checkerboard FICI Time-kill FICI
H041 ETX0914 + CIP 1.0–2.2 1.3
WHO F ETX0914 + CIP 0.5–1.0 0.4
WHO O ETX0914 + CIP 0.5–1.0 1.6
OM-5 ETX0914 + CIP 0.4–1.0 0.1
WHO P ETX0914 + CIP 0.8–2.0 1.6
PM-4 ETX0914 + CIP 0.4–1.0 0.1
H041 ETX0914 + AZM 2.0–3.0 1.5
WHO F ETX0914 + AZM 1.0–1.5 1.3
WHO O ETX0914 + AZM 0.6–1.0 0.7
OM-5 ETX0914 + AZM 0.6–2.0 1.7
WHO P ETX0914 + AZM 1.0–2.5 2.2
PM-4 ETX0914 + AZM 1.0–1.2 0.9
H041 ETX0914 + CRO 1.0–2.0 1.3
WHO F ETX0914 + CRO 1.0–1.5 1.1
WHO O ETX0914 + CRO 1.0–2.0 1.4
OM-5 ETX0914 + CRO 0.6–1.0 0.8
WHO P ETX0914 + CRO 0.6–1.2 0.3
PM-4 ETX0914 + CRO 0.5–1.2 0.02
H041 ETX0914 + TET 2.0–8.0 1.9
WHO F ETX0914 + TET 1.0–2.0 2.1
WHO O ETX0914 + TET 1.0–1.2 0.9
OM-5 ETX0914 + TET 1.0–2.0 0.9
WHO P ETX0914 + TET 1.0–1.5 2.3
PM-4 ETX0914 + TET 0.8–1.1 1.8
CIP, ciprofloxacin; AZM, azithromycin; CRO, ceftriaxone; TET, tetracycline.
DISCUSSION
This study extends the characterization of N. gonorrhoeae
resistance determinants for the novel spiropyrimidinetrione
ETX0914; the new D429A resistance mutation in GyrB was
identiﬁed and it was shown that theMtrCDE eﬄux pump exports
ETX0914 (MtrCDE inactivation restored susceptibility to wild
type MIC levels). The eﬀects of ETX0914 on the growth of
N. gonorrhoeae (ETX0914 wild type, single step selected resistant
mutants, and eﬄux pump mutants) were detailed in a novel
in vitro time-kill curve analysis to estimate pharmacodynamic
parameters (Foerster et al., 2015) of the new antimicrobial.
For comparison, ciproﬂoxacin, azithromycin, ceftriaxone and
tetracycline were also investigated, separately and in combination
with ETX0914, using time-kill curve analysis and checkerboard
analysis. ETX0914was rapidly bactericidal for all wild type strains
and had similar pharmacodynamic properties to ciproﬂoxacin.
ETX0914 in combination with azithromycin and ceftriaxone was
highly eﬀective and synergistic interaction with ciproﬂoxacin,
particularly for ETX0914-resistant mutants, was also found.
Single step ETX0914-resistant mutants, ETX0914 MICs of
0.5–4 mg/L, were selected at very low frequencies on GC agar
plates (<1.9 × 10−14) from the wild type N. gonorrhoeae WHO
F, O, and P strains, but not from H041. All resistant mutants
had mutations in the DNA gyrase subunit GyrB. In addition
to previously identiﬁed gyrB D429N and K450T mutations
in selected ETX0914-resistant mutants (Alm et al., 2015), the
present study also found a D429Amutation in one of the resistant
mutants. Interestingly, using the more nutritious GCAGP agar
medium (including also 1% hemoglobin and 10% horse serum)
and selection during 72 h incubation, resistant mutants were
obtained from all four strains and in a higher frequency, that
is, with a frequency of 5 × 10−9 for WHO F, 1 × 10−8 for
WHO O and WHO P, and 8 × 10−9 for H041, consistent
with a previous publication (Alm et al., 2015). Notably, no gyrB
mutations were found in H041. The choice of medium used for
selecting mutants strongly inﬂuences the mutational frequency,
which shows the diﬃculties of predicting how rapidly resistance
to ETX0914 will be selected in vivo. Furthermore, in the present
study it was also obvious that the resistance mutations in gyrB
reduced the growth rates compared to their isogenic wild type
strains and this decreased biological ﬁtness might also make
it diﬃcult to predict the initial spread of ETX0914-resistant
mutants in vivo.
Inactivation of the MtrCDE eﬄux pump increased
susceptibility in wild type strains and restored the susceptibility to
wild type levels in the selected ETX0914-resistant mutants (from
2–4 mg/L to 0.125 mg/L). In one strain (H041), inactivation of
also the MacAB and NorM eﬄux pumps substantially decreased
the MIC of ETX0914 (from 0.125 mg/L to 0.008 mg/L). This
shows that eﬄux pumps, especially the MtrCDE pump, can
inﬂuence susceptibility to ETX0914.
Pharmacodynamic modeling and prediction of the eﬃcacy
of diﬀerent dosing regimens for ceﬁxime and ceftriaxone have
been previously performed using a combination of clinical data
and in vitro data (Chisholm et al., 2010). There is, however, no
appropriate in vitro method to determine whether single dose
or multiple doses of new antimicrobials, such as ETX0914, in
monotherapy or in dual therapy provide eﬀective bactericidal
activity. The present study quantiﬁed the antibacterial eﬀects of
ETX0914 and compared the results to those of previously or
currently used antimicrobials by calculating the net growth rates
from time-kill curve analysis and ﬁtting a pharmacodynamic
function to the time-kill curve data. The highest concentration
included was 16 × MIC (measured with agar dilution technique
prior to the experiment), to avoid toxic oﬀ-target eﬀects that
can occur at unrealistically high antimicrobial concentrations.
For all wild type strains, ETX0914 exhibited bactericidal activity
(>99.9% killing) after only 4 h at 8 × MIC and 16 × MIC, and
more gradual bactericidal activity at 2 × MIC and 4 × MIC
in the susceptible strains, but not in the mutants. Analysis of
the pharmacodynamic function to predict the concentration-
and time-dependent properties of antimicrobials from time-
kill curve data was established in an Escherichia coli model
(Regoes et al., 2004). For antimicrobials with a steep slope of the
pharmacodynamic relationship, as characterized by a high value
for the Hill coeﬃcient (parameter κ), the Cmax/MIC ratio should
be maximized, showing concentration dependency. When MIC,
steepness of the slope of the pharmacodynamic function (Hill
coeﬃcient; parameter κ) and maximal bacterial net growth rate
in the absence of antimicrobial (ψmax) were equal, low values
of the minimal bacterial net growth rate at high concentrations
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of antimicrobial (ψmin) were suggested to predict eﬃcacy of the
antimicrobial. That study, however, only examined a single E. coli
strain over a time-course of 70 min (Regoes et al., 2004). The
present study examined the parameters of the pharmacodynamic
function for several diﬀerent N. gonorrhoeae strains (wild type
and selected ETX0914-resistant mutants) and an extended 6 h
sampling window. An excellent correlation between the zMIC
and the MIC measured with Etest or agar dilution technique was
found, despite the diﬀerent growth medium and exposure time.
This indicates that the time-kill curve analysis was optimized,
quality assured and consistent. The highest deviations were found
for ceftriaxone, probably because the sampling period of 6 h
was too short to capture the full eﬀect of this time-dependent
antimicrobial.
Hierarchical clustering also helped to ﬁnd similarities across
antimicrobials and strains. The “minimal growth rate” (ψmin)
summarized the highest killing rate measured within the 6 h
assay time in response to the antimicrobial. The values for
the “minimal growth rate” (ψmin) were much higher in the
isogenic ETX0914-resistant mutants compared to the susceptible
wild type strains and these clustered together. Nevertheless,
additional work is needed to evaluate whether this increase
in the “minimal growth rate” (ψmin) is characteristic of gyrB
mutations or if it is generalizable to other resistance mechanisms
and antimicrobials. In general, ETX0914 and ciproﬂoxacin
showed the highest similarity in the clustering across all strains,
which is not surprising considering that both compounds target
the same enzyme(s) and are mechanistically quite similar.
These similarities are not captured by means of conventional
MIC determinations alone. The time-kill curve analysis and
subsequent pharmacodynamic analyses used in this study
provide additional information. The hierarchical clustering of
values of the steepness of the slope of the pharmacodynamic
function (Hill coeﬃcient; parameter κ) resulted in a less clear
pattern and the Hill coeﬃcient (κ) diﬀered greatly between
strains but not signiﬁcantly in the mutants compared to the
wild type strains. There was a non-signiﬁcant trend for steeper
slopes of the pharmacodynamic functions [higher Hill coeﬃcient
(κ) values] in the time-dependent antimicrobial ceftriaxone and
the bacteriostatic compound tetracycline compared to the more
bactericidal azithromycin, ETX0914 and ciproﬂoxacin.
The results of in vitro time-kill curve analysis and
pharmacodynamic functions for ciproﬂoxacin, azithromycin,
ceftriaxone, and tetracycline were, in general, consistent with
previous ﬁndings using other pharmacodynamic analysis
methods (Drusano, 2004). For drugs like ﬂuoroquinolones (e.g.,
ciproﬂoxacin) and macrolides (e.g., azithromycin), a high ratio
of maximum concentration to MIC (Cmax/MIC ratio) predicts
a successful treatment outcome (Li et al., 1999; Drusano, 2004).
This requires maximizing the dose given to a patient. ETX0914
was rapidly bactericidal with a pharmacodynamic proﬁle similar
to ciproﬂoxacin, so maximizing the concentration of ETX0914
in a single dose should be highly eﬀective. In contrast, for
time-dependent drugs (including β-lactams and tetracyclines) a
long time of free antimicrobial above MIC (fT/MIC ratio) or a
large ratio of the area under the pharmacokinetic curve to MIC
(AUC/MIC) predicts a successful treatment outcome. Therefore,
several smaller doses or continuous infusions to maximize the
time above MIC can have a better treatment outcome than one
large dose (Jacobs, 2001; Drusano, 2004; Asín-Prieto et al., 2015).
Combinations of ETX0914 with ciproﬂoxacin, azithromycin,
ceftriaxone, or tetracycline were explored comparing FICIs from
the time-kill curve analysis and checkerboard assay. In general,
the results of the time-kill curve analysis and checkerboard assay
were concordant, but the error for estimating the zMIC was
high in some pharmacodynamic models and this was reﬂected
in the uncertainty of the FICI values. ETX0914 and ciproﬂoxacin
showed synergy particularly in the ETX0914 resistant mutants.
It was also recently found that speciﬁc gyrB mutations might
result in a conformational change creating a more favorable
binding pocket for ciproﬂoxacin and, accordingly, a decreased
ciproﬂoxacin MIC in ciproﬂoxacin-resistant N. gonorrhoeae
strains (Alm et al., 2015) as well as the fact that K450T mutation,
resulting in ETX0914 resistance, conveys increased susceptibility
to ciproﬂoxacin (Kern et al., 2015). The combination of ETX0914
and ciproﬂoxacin might be beneﬁcial because ETX0914 acts
bactericidal on ciproﬂoxacin resistant strains and vice versa. The
drug interaction between ETX0914 and ciproﬂoxacin strengthens
the hypothesis of two diﬀerent targets that inﬂuence each
other. Non-competitive inhibition of the same enzyme by two
antimicrobials that follow the rule of Bliss independence will
also lead to synergy in a theoretical model based on Michaelis
Menten kinetics (Breitinger, 2012). The combination of ETX0914
with azithromycin showed a more rapid killing in a qualitative
analysis of the time-kill curve and no antagonism was observed
for any of the examined strains in the time-kill curve analysis or
checkerboard assays. These results indicate that ETX0914 could
also be beneﬁcially administered together with azithromycin
in an oral dual antimicrobial therapy, which also would be
able to treat concomitant sexually transmitted infections such
as Chlamydia trachomatis and many Mycoplasma genitalium
infections.
CONCLUSION
ETX0914 (AZD0914) was rapidly bactericidal and had similar
pharmacodynamic properties to ciproﬂoxacin. Speciﬁc
mutations in GyrB result in resistance to ETX0914 and
MtrCDE inactivation restore susceptibility to wild type levels.
ETX0914 alone and in dual combinations with ciproﬂoxacin,
azithromycin, or ceftriaxone were highly eﬀective against
N. gonorrhoeae. ETX0914, as oral monotherapy or combined
with azithromycin (to cover also additional sexually transmitted
infections), should be considered for appropriate Phase III
clinical trials and future gonorrhea treatment.
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